Tyme Announces Presentation of Clinical Data on SM-88 in Prostate Cancer at 2018 ASCO Genitourinary Cancers Symposium Mack Roach, M.D., FASCO, University of California, San Francisco, to present data from ongoing Phase II clinical trial Tyme Inc. announced that data from the ongoing Phase II clinical trial of its lead therapy SM-88 in patients with non-metastatic biochemical recurrent prostate cancer will be presented by Mack Roach, M.D., FASCO, University of California, San Francisco, in a poster session at the 2018…